Global RNAi for Therapeutic Market Research Report, Competitive, Technology and Forecast Analysis 2025-2032
Description
Market Overview
According to DIResearch's in-depth investigation and research, the global RNAi for Therapeutic market size will reach 537.20 Million USD in 2025 and is projected to reach 5,696.88 Million USD by 2032, with a CAGR of 40.12% (2025-2032). Notably, the China RNAi for Therapeutic market has changed rapidly in the past few years. By 2025, China's market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
RNA interference (RNAi) for therapeutic purposes involves harnessing the natural biological process of RNAi to selectively and precisely regulate gene expression within cells. RNAi is a mechanism where small RNA molecules, such as small interfering RNA (siRNA) or microRNA (miRNA), interfere with the translation or stability of specific messenger RNA (mRNA) molecules, thereby preventing the synthesis of a particular protein. In therapeutic applications, researchers design and deliver synthetic RNA molecules to target and silence disease-associated genes, offering a potential strategy for treating various genetic disorders, viral infections, and certain cancers. RNAi therapeutics aim to exploit this precise gene-silencing mechanism to intervene at the molecular level and correct or mitigate the underlying causes of diseases. While challenges such as effective delivery and off-target effects need to be addressed, RNAi holds significant promise as a novel and targeted approach in the field of personalized medicine and therapeutic development.
The major global suppliers of RNAi for Therapeutic include Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, Quark Pharmaceuticals, RXi Pharmaceuticals, Benitec Biopharma, Silence Therapeutics, Sylentis, miRagen Therapeutics, Gradalis, Sirnaomics, Silenseed, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of RNAi for Therapeutic. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global RNAi for Therapeutic market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the RNAi for Therapeutic market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of RNAi for Therapeutic industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of RNAi for Therapeutic Include:
Alnylam Pharmaceuticals
Arbutus Biopharma (Tekmira)
Arrowhead
Dicerna Pharmaceuticals
Mirna Therapeutics
Quark Pharmaceuticals
RXi Pharmaceuticals
Benitec Biopharma
Silence Therapeutics
Sylentis
miRagen Therapeutics
Gradalis
Sirnaomics
Silenseed
RNAi for Therapeutic Product Segment Include:
siRNA
miRNA
shRNA
RNAi for Therapeutic Product Application Include:
Cancer
Cardiovascular
HBV
Others
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global RNAi for Therapeutic Industry PESTEL Analysis
Chapter 3: Global RNAi for Therapeutic Industry Porter's Five Forces Analysis
Chapter 4: Global RNAi for Therapeutic Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global RNAi for Therapeutic Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global RNAi for Therapeutic Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, RNAi for Therapeutic Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
According to DIResearch's in-depth investigation and research, the global RNAi for Therapeutic market size will reach 537.20 Million USD in 2025 and is projected to reach 5,696.88 Million USD by 2032, with a CAGR of 40.12% (2025-2032). Notably, the China RNAi for Therapeutic market has changed rapidly in the past few years. By 2025, China's market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
RNA interference (RNAi) for therapeutic purposes involves harnessing the natural biological process of RNAi to selectively and precisely regulate gene expression within cells. RNAi is a mechanism where small RNA molecules, such as small interfering RNA (siRNA) or microRNA (miRNA), interfere with the translation or stability of specific messenger RNA (mRNA) molecules, thereby preventing the synthesis of a particular protein. In therapeutic applications, researchers design and deliver synthetic RNA molecules to target and silence disease-associated genes, offering a potential strategy for treating various genetic disorders, viral infections, and certain cancers. RNAi therapeutics aim to exploit this precise gene-silencing mechanism to intervene at the molecular level and correct or mitigate the underlying causes of diseases. While challenges such as effective delivery and off-target effects need to be addressed, RNAi holds significant promise as a novel and targeted approach in the field of personalized medicine and therapeutic development.
The major global suppliers of RNAi for Therapeutic include Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, Quark Pharmaceuticals, RXi Pharmaceuticals, Benitec Biopharma, Silence Therapeutics, Sylentis, miRagen Therapeutics, Gradalis, Sirnaomics, Silenseed, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of RNAi for Therapeutic. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global RNAi for Therapeutic market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the RNAi for Therapeutic market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of RNAi for Therapeutic industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of RNAi for Therapeutic Include:
Alnylam Pharmaceuticals
Arbutus Biopharma (Tekmira)
Arrowhead
Dicerna Pharmaceuticals
Mirna Therapeutics
Quark Pharmaceuticals
RXi Pharmaceuticals
Benitec Biopharma
Silence Therapeutics
Sylentis
miRagen Therapeutics
Gradalis
Sirnaomics
Silenseed
RNAi for Therapeutic Product Segment Include:
siRNA
miRNA
shRNA
RNAi for Therapeutic Product Application Include:
Cancer
Cardiovascular
HBV
Others
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global RNAi for Therapeutic Industry PESTEL Analysis
Chapter 3: Global RNAi for Therapeutic Industry Porter's Five Forces Analysis
Chapter 4: Global RNAi for Therapeutic Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global RNAi for Therapeutic Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global RNAi for Therapeutic Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, RNAi for Therapeutic Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
Table of Contents
165 Pages
- 1 RNAi for Therapeutic Market Overview
- 1.1 Product Definition and Statistical Scope
- 1.2 RNAi for Therapeutic Product by Type
- 1.2.1 siRNA
- 1.2.2 miRNA
- 1.2.3 shRNA
- 1.3 RNAi for Therapeutic Product by Application
- 1.3.1 Cancer
- 1.3.2 Cardiovascular
- 1.3.3 HBV
- 1.3.4 Others
- 1.4 Global RNAi for Therapeutic Market Size Analysis (2020-2032)
- 1.5 RNAi for Therapeutic Market Development Status and Trends
- 1.5.1 RNAi for Therapeutic Industry Development Status Analysis
- 1.5.2 RNAi for Therapeutic Industry Development Trends Analysis
- 2 RNAi for Therapeutic Market PESTEL Analysis
- 2.1 Political Factors Analysis
- 2.2 Economic Factors Analysis
- 2.3 Social Factors Analysis
- 2.4 Technological Factors Analysis
- 2.5 Environmental Factors Analysis
- 2.6 Legal Factors Analysis
- 3 RNAi for Therapeutic Market Porter's Five Forces Analysis
- 3.1 Competitive Rivalry
- 3.2 Threat of New Entrants
- 3.3 Bargaining Power of Suppliers
- 3.4 Bargaining Power of Buyers
- 3.5 Threat of Substitutes
- 4 Global RNAi for Therapeutic Market Analysis by Country
- 4.1 Global RNAi for Therapeutic Market Size Analysis by Country: 2024 VS 2025 VS 2032
- 4.1.1 Global RNAi for Therapeutic Revenue Analysis by Country (2020-2025)
- 4.1.2 Global RNAi for Therapeutic Revenue Forecast Analysis by Country (2026-2032)
- 4.2 United States RNAi for Therapeutic Market Revenue and Growth Rate (2020-2032)
- 4.3 Germany RNAi for Therapeutic Market Revenue and Growth Rate (2020-2032)
- 4.4 Japan RNAi for Therapeutic Market Revenue and Growth Rate (2020-2032)
- 4.5 China RNAi for Therapeutic Market Revenue and Growth Rate (2020-2032)
- 4.6 France RNAi for Therapeutic Market Revenue and Growth Rate (2020-2032)
- 4.7 U.K. RNAi for Therapeutic Market Revenue and Growth Rate (2020-2032)
- 4.8 South Korea RNAi for Therapeutic Market Revenue and Growth Rate (2020-2032)
- 4.9 Canada RNAi for Therapeutic Market Revenue and Growth Rate (2020-2032)
- 4.10 Italy RNAi for Therapeutic Market Revenue and Growth Rate (2020-2032)
- 4.11 Russia RNAi for Therapeutic Market Revenue and Growth Rate (2020-2032)
- 4.12 Mexico RNAi for Therapeutic Market Revenue and Growth Rate (2020-2032)
- 4.13 Brazil RNAi for Therapeutic Market Revenue and Growth Rate (2020-2032)
- 4.14 India RNAi for Therapeutic Market Revenue and Growth Rate (2020-2032)
- 4.15 Vietnam RNAi for Therapeutic Market Revenue and Growth Rate (2020-2032)
- 4.16 Thailand RNAi for Therapeutic Market Revenue and Growth Rate (2020-2032)
- 4.17 South Africa RNAi for Therapeutic Market Revenue and Growth Rate (2020-2032)
- 5 Competition by Suppliers
- 5.1 Global RNAi for Therapeutic Market Revenue by Key Suppliers (2021-2025)
- 5.2 RNAi for Therapeutic Competitive Landscape Analysis and Market Dynamic
- 5.2.1 RNAi for Therapeutic Competitive Landscape Analysis
- 5.2.2 Global Key Suppliers Headquarter and Key Area Sales
- 5.2.3 Market Dynamic
- 6 RNAi for Therapeutic Market Analysis by Type
- 6.1 Global RNAi for Therapeutic Market Size Analysis by Type: 2024 VS 2025 VS 2032
- 6.2 Global RNAi for Therapeutic Revenue and Forecast Analysis by Type (2020-2032)
- 7 Key Companies Analysis
- 7.1 Alnylam Pharmaceuticals
- 7.1.1 Alnylam Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.1.2 Alnylam Pharmaceuticals RNAi for Therapeutic Product Portfolio
- 7.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.2 Arbutus Biopharma (Tekmira)
- 7.2.1 Arbutus Biopharma (Tekmira) Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.2.2 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Product Portfolio
- 7.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.3 Arrowhead
- 7.3.1 Arrowhead Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.3.2 Arrowhead RNAi for Therapeutic Product Portfolio
- 7.3.3 Arrowhead RNAi for Therapeutic Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.4 Dicerna Pharmaceuticals
- 7.4.1 Dicerna Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.4.2 Dicerna Pharmaceuticals RNAi for Therapeutic Product Portfolio
- 7.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.5 Mirna Therapeutics
- 7.5.1 Mirna Therapeutics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.5.2 Mirna Therapeutics RNAi for Therapeutic Product Portfolio
- 7.5.3 Mirna Therapeutics RNAi for Therapeutic Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.6 Quark Pharmaceuticals
- 7.6.1 Quark Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.6.2 Quark Pharmaceuticals RNAi for Therapeutic Product Portfolio
- 7.6.3 Quark Pharmaceuticals RNAi for Therapeutic Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.7 RXi Pharmaceuticals
- 7.7.1 RXi Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.7.2 RXi Pharmaceuticals RNAi for Therapeutic Product Portfolio
- 7.7.3 RXi Pharmaceuticals RNAi for Therapeutic Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.8 Benitec Biopharma
- 7.8.1 Benitec Biopharma Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.8.2 Benitec Biopharma RNAi for Therapeutic Product Portfolio
- 7.8.3 Benitec Biopharma RNAi for Therapeutic Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.9 Silence Therapeutics
- 7.9.1 Silence Therapeutics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.9.2 Silence Therapeutics RNAi for Therapeutic Product Portfolio
- 7.9.3 Silence Therapeutics RNAi for Therapeutic Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.10 Sylentis
- 7.10.1 Sylentis Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.10.2 Sylentis RNAi for Therapeutic Product Portfolio
- 7.10.3 Sylentis RNAi for Therapeutic Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.11 miRagen Therapeutics
- 7.11.1 miRagen Therapeutics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.11.2 miRagen Therapeutics RNAi for Therapeutic Product Portfolio
- 7.11.3 miRagen Therapeutics RNAi for Therapeutic Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.12 Gradalis
- 7.12.1 Gradalis Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.12.2 Gradalis RNAi for Therapeutic Product Portfolio
- 7.12.3 Gradalis RNAi for Therapeutic Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.13 Sirnaomics
- 7.13.1 Sirnaomics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.13.2 Sirnaomics RNAi for Therapeutic Product Portfolio
- 7.13.3 Sirnaomics RNAi for Therapeutic Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.14 Silenseed
- 7.14.1 Silenseed Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.14.2 Silenseed RNAi for Therapeutic Product Portfolio
- 7.14.3 Silenseed RNAi for Therapeutic Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 8 Industry Chain Analysis
- 8.1 RNAi for Therapeutic Industry Chain Analysis
- 8.2 RNAi for Therapeutic Product Downstream Application Analysis
- 8.2.1 Global RNAi for Therapeutic Market Size and Growth Rate (CAGR) by Application: 2024 VS 2025 VS 2032
- 8.2.2 Global RNAi for Therapeutic Revenue and Forecast by Application (2020-2032)
- 8.3 RNAi for Therapeutic Typical Downstream Customers
- 8.4 RNAi for Therapeutic Sales Channel Analysis
- 9 Research Findings and Conclusion
- 10 Methodology and Data Source
- 10.1 Methodology/Research Approach
- 10.2 Research Scope
- 10.3 Benchmarks and Assumptions
- 10.4 Date Source
- 10.4.1 Primary Sources
- 10.4.2 Secondary Sources
- 10.5 Data Cross Validation
- 10.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
